The effects of the antifibrotic drug Halofuginone hydrobromide (Halo) on muscle function, regeneration and cardiorespiratory function were studied using mdx mice. It was hypothesized that Halo treatment would resolve pre-established fibrosis and prevent collagen deposits, improving muscle and cardio-respiratory function.
Mice 8-9 mos were treated with saline or Halo for 5 (n = 4/group), 10 (n = 5/group) and 12 weeks (n = 4-5/group). Muscle strength and endurance, respiration and muscle susceptibility to damage were assessed. Tissues were collected from all mice. Additional mice were treated for 10 wks (3-4 wks n = 9-10/group; 8-9 mos n = 8-9/group) for echocardiography.
Halo reduced fibrosis. As a consequence, there was muscle repair and damage was reduced. There were functional improvements and disease progression was slowed. There was resolution of pre-existing fibrosis and reduction of new collagen synthesis. This treatment could improve quality of life and lengthen the lifespan of DMD patients. / May 2007
| Identifer | oai:union.ndltd.org:LACETR/oai:collectionscanada.gc.ca:MWU.anitoba.ca/dspace#1993/329 |
| Date | 26 April 2007 |
| Creators | Huebner, Kyla Danielle |
| Contributors | Anderson, Judith (Human Anatomy and Cell Science), Thliveris, James (Human Anatomy and Cell Science) Scott, Elliott (Oral Biology) |
| Source Sets | Library and Archives Canada ETDs Repository / Centre d'archives des thèses électroniques de Bibliothèque et Archives Canada |
| Language | en_US |
| Detected Language | English |
| Format | 25937408 bytes, 5231616 bytes, 1483776 bytes, 8609280 bytes, 2305819 bytes, application/octet-stream, application/octet-stream, application/octet-stream, application/octet-stream, application/pdf |
Page generated in 0.0019 seconds